Cellular Generation and Phenotyping
Cell Biology Research
Organoid culture: generation of new cancer organoid models and performing genome-wide CRISPR/Cas9 knockout screens in cancer/patient-derived organoid lines to identify genes essential for survival (Project Gro and Score 3D)
Neural differentiation: differentiation of knockout hiPSC lines into neural stem cells (DDD-NeuGen) and cortical neurons in the presence of glial proteins, to study their effects on synapse formation (iNeurons).
CRISPR/Cas9 screening: identification of novel synthetically lethal gene targets in cancer lines (CRISPR Adams) and measuring variability in human gene essentiality in healthy individuals using hiPSCs (Parts HiPSCi).
Histology: processing tissue samples to section, stain and analyse anatomical structures under light or fluorescent microscopes, using H&E, Visium and RNAscope (Histology service). Donor tissue dissociation into single cell resolution to carry out RNA-Seq, to create a reference map of all cells in the human body (HCA project).
COG-UK: CGaP plays an instrumental role in the Institute’s contribution to the COVID-19 Genomics UK Consortium, involving large-scale, nation-wide virus sample and metadata collection, preparation, sequencing, analysis and data visualisation.
Media team: supporting our research, we have a dedicated team that produces coated cultureware, reagents and specialist media to order. They also provide mycoplasma screening, sterility testing, reagent batch testing and cell banking services for CGaP and other teams within Cellular Operations.
Work in the group is underpinned by a research and development function which undertakes continual improvement across the group in order to introduce new techniques and to increase capacity and quality of existing ones.
Members of CGaP volunteer their time to be part of the Technician Commitment (TC). The TC aims to increase the visibility and recognition of technical staff across the Institute, as well as promoting their career development and sustainability of this national initiative. The TC is led by a Steering Committee who ensure the delivery of the action plan, across six different working groups. CGaP TC members are represented across the ‘Marketing and Communications Working Group, and the ‘Events Working Group’. To see the impact these working groups are having at the Institute then please look at the Technician Commitment page.
As a team we are dedicated to sharing our expertise internally within the institute, and externally. This includes through providing internal training courses through the Technician Commitment, and external iPSC culture training through the Wellcome Genome Campus Advanced Courses.
CGaP’s charity team are responsible for organising fundraising events to support local Cambridgeshire charities. These fundraising events are a mixture of smaller internal events and large annual events put out across the Institute. As well as fundraising events, CGaP’s charity team will promote and volunteer for local charities, using the Institute’s 2 full-paid volunteering days initiative.
Our first event was a huge success. We raised over £1000 for Arthur Rank Hospice and CPSL Mind through our 5 million steps throughout July 2020 challenge. We hope to replicate this success in future events.
Our expertise in large-scale research means that our protocols have been rigorously tested to ensure they are robust, effective and highly replicable. We believe that there is great value in sharing such protocols amongst the scientific community, for other labs to discover and easily compare the specifics of their methodologies to other groups practicing similar work.
Click here to find all of CGaP’s published protocols.
Click here to read a blog post, in which we explain our reasons for sharing our protocols with the wider scientific community.
Previous team members
Utilising a bespoke paired guide CRISPR library to identify novel synthetically lethal gene targets in multiple cancer types. The project involves ...
Cancer Dependency Map
CGaP performs Genome-wide Synthetic-lethal CRISPR-Cas-9 screens in Cancer cell lines and Organoids to identify cancer essential genes.
The DDD-NeuGen project investigates how de novo mutations that cause rare development disorders impact neural development and gene expression.
Deciphering Developmental Disorders (DDD)
The aim of the Deciphering Developmental Disorders (DDD) Study is to advance clinical genetic practice for children with developmental disorders by ...
EBiSC - European Bank for induced pluripotent Stem Cells
The European Bank for induced pluripotent Stem Cells (EBiSC) is a large European public-private partnership project supported jointly by the Innovative ...
Providing researchers with technical histological support and wet lab data. Areas of expertise include tissue processing, sectioning, staining, bright field/fluorescent ...
Human Cancer Models Initiative (HCMI)
As part of a 2 year pilot phase we have derived over 100 new 3D organoid models from colon, oesophageal and ...
Human Cell Atlas
The International Human Cell Atlas initiative aims to create comprehensive reference maps of all human cells.
The Organoids project involves the derivation, culture, banking and genetic validation of organoid cell lines produced from tumour samples taken from ...
Measuring the variability in human gene essentiality across healthy individuals. The project involves performing whole genome CRISPR-Cas9 screens in multiple HipSci ...
Dedicated to performing genome-wide loss-of-function CRISPR-Cas9 screens in cancer organoids and cell lines, to identify synthetic-lethal interaction between cancer genomes and ...
Experimental Cancer Genetics
We are a team of cancer biologists, geneticists and computational biologists interested in understanding how cancers develop and the ways of ...
Cellular and Gene Editing Research
We develop novel genome editing techniques, cellular differentiation and cellular phenotyping systems, especially with respect to high-throughput investigation of gene and ...
Cytometry Core Facility
The Cytometry Core Facility at the Wellcome Trust Sanger Institute is a dedicated scientific service offering investigators with state-of-the-art flow cytometry ...
Translational Cancer Genomics
The Translational Cancer Genomics team investigate how genetic alterations in cancer contribute to disease and impact on response to therapy.
In collaboration with our colleagues in Cellular Operations and Stem Cell Informatics, our work focuses on supporting and delivering the gene ...
Genomic mutation and genetic disease
The Hurles group studies the genetic causes and mechanisms of rare genetic disorders and how DNA mutates as it is pass ...
Function of human DNA and its variation
Our goal is to understand how genetic background influences outcome of mutations. To do so, we measure, model, and modulate cell ...
Stem Cell Informatics
Stem Cell Informatics (SCI) develops custom laboratory information systems (LIMS) and computational research tools (WGE) for high-throughput laboratory analysis of human ...
Gene expression genomics
We use cutting edge single cell genomics technologies and computational methods to understand genes, proteins and cells in human health and ...
Genomics of gene regulation
Gene expression involves the transformation of genetic information encoded in DNA sequence into a gene product, such as a protein. Regulation ...
High throughput gene editing
The High Throughput Gene Editing team helped to deliver the gene editing requirements of the Institute's faculty and research
Programmes and Facilities
We work with the following groups
HipSci brings together diverse constituents in genomics, proteomics, cell biology and clinical genetics to create a UK national iPS cell resource and use it to carry out cellular genetic studies. Between 2013 and 2016 we aim to generate iPS cells from over 500 healthy individuals and 500 individuals with genetic disease. We will then use these cells to discover how genomic variation impacts on cellular phenotype and identify new disease mechanisms.
INSIGNIA is a study focused on the investigation of patterns of mutations (signatures) in inherited and other progressive genetic diseases.Cancer is the ultimate genetic disease characterised by many thousands of mutations that accumulate within the genome of a cancer patient. The sets of mutations observed in a cancer genome are the overall outcome of a number of different mutational processes. These are caused by an underlying mechanism of DNA damage, and subsequent attempts by the cell to repair that damage. As a result, each mutational process will leave a distinctive mark or mutational signature on the cancer genome.In the same way that counting tree rings can tell us about the age and growth of that tree, the mutational signatures 'buried in the genome' can provide us with information on the biological changes that have occurred during the course of cancer (or other genetic disease) development.
OpenTargets is a unique public-private initiative to apply cutting edge genetics research to the problem of drug taregt identification and validation. They have generously funded several projects in our lab on the application of CRISPR technology to human IPS-derived model systems